FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595184800> ?p ?o ?g. }

• W2595184800 endingPage "150" @default.
• W2595184800 startingPage "147" @default.
• W2595184800 abstract "In patients with atrial fibrillation (AF) pharmacological or electrical cardioversion may be performed to restore sinus rhythm. The procedure is associated with an increased risk of thromboembolic events, which can be significantly reduced by adequate anticoagulation (OAC). Our aim was to create a partly prospective, partly retrospective cardioversion registry, particularly focusing on OAC strategies in different European countries, and on emerging choice of OAC over time. From September 2014 to October 2015, cardioversions due to AF performed in six European city hospitals in five European countries (Hungary: Budapest-1 and -2; Italy: Bari and Pisa; France: Amiens; Spain: Madrid; and Lithuania: Kaunas) were recorded in the registry. A total of 1101 patients (retrospective/prospective: 679/422, male/female: 742/359, mean age: 67.3 years ± 11.2) were registered. Most of the cardioversions were electrical (97%). Oral anticoagulants were administered in 87% of the patient, the usage of non-VKA oral anticoagulants (NOACs) vs Vitamin K antagonists (VKA) was 31.5% vs 68.5%, respectively. Seventy seven percent of the patients were given oral anticoagulants more than 3 weeks prior to the procedure, and 86% more than 4 weeks after the procedure. When using VKA, international normalized ratio (INR) at cardioversion was above 2.0 in 76% of the cases. A decline in VKA usage (P = 0.033) in elective cardioversion over approximately 1 year was observed. During the observation period, there was an increase in apixaban (P < 0.001), a slight increase in rivaroxaban (P = 0.028) and no changes in dabigatran (P = 0.34) usage for elective cardioversion. There were differences in use of OAC between the countries: Spain used most VKA (89%), while France used least VKA (39%, P < 0.001). According to current AF guidelines, NOACs are adequate alternatives to VKA for thromboembolic prevention in AF patients undergoing elective cardioversion. Our results indicate that NOAC use is increasing and there is a significant decrease in VKA use." @default.
• W2595184800 created "2017-03-23" @default.
• W2595184800 creator A5005672064 @default.
• W2595184800 creator A5006283505 @default.
• W2595184800 creator A5009926169 @default.
• W2595184800 creator A5012835670 @default.
• W2595184800 creator A5022123282 @default.
• W2595184800 creator A5033873028 @default.
• W2595184800 creator A5065609260 @default.
• W2595184800 creator A5076961983 @default.
• W2595184800 creator A5079494067 @default.
• W2595184800 creator A5079603579 @default.
• W2595184800 creator A5083377034 @default.
• W2595184800 date "2017-03-17" @default.
• W2595184800 modified "2023-10-03" @default.
• W2595184800 title "Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry" @default.
• W2595184800 cites W2017922054 @default.
• W2595184800 cites W206978033 @default.
• W2595184800 cites W2095661544 @default.
• W2595184800 cites W2096246254 @default.
• W2595184800 cites W2097692121 @default.
• W2595184800 cites W2097854437 @default.
• W2595184800 cites W2121394112 @default.
• W2595184800 cites W2127134885 @default.
• W2595184800 cites W2136489990 @default.
• W2595184800 cites W2148229222 @default.
• W2595184800 cites W2159357148 @default.
• W2595184800 cites W2161054439 @default.
• W2595184800 cites W2162508946 @default.
• W2595184800 cites W2171346361 @default.
• W2595184800 cites W2177732078 @default.
• W2595184800 cites W2184610045 @default.
• W2595184800 cites W2418151246 @default.
• W2595184800 cites W2488046539 @default.
• W2595184800 cites W2509795914 @default.
• W2595184800 cites W2510777240 @default.
• W2595184800 cites W2513776588 @default.
• W2595184800 cites W2515488477 @default.
• W2595184800 cites W2517494398 @default.
• W2595184800 cites W2527161344 @default.
• W2595184800 cites W2593460085 @default.
• W2595184800 cites W3004050106 @default.
• W2595184800 cites W4205645630 @default.
• W2595184800 doi "https://doi.org/10.1093/ehjcvp/pvx003" @default.
• W2595184800 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5843131" @default.
• W2595184800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28329309" @default.
• W2595184800 hasPublicationYear "2017" @default.
• W2595184800 type Work @default.
• W2595184800 sameAs 2595184800 @default.
• W2595184800 citedByCount "16" @default.
• W2595184800 countsByYear W25951848002017 @default.
• W2595184800 countsByYear W25951848002018 @default.
• W2595184800 countsByYear W25951848002019 @default.
• W2595184800 countsByYear W25951848002020 @default.
• W2595184800 countsByYear W25951848002021 @default.
• W2595184800 crossrefType "journal-article" @default.
• W2595184800 hasAuthorship W2595184800A5005672064 @default.
• W2595184800 hasAuthorship W2595184800A5006283505 @default.
• W2595184800 hasAuthorship W2595184800A5009926169 @default.
• W2595184800 hasAuthorship W2595184800A5012835670 @default.
• W2595184800 hasAuthorship W2595184800A5022123282 @default.
• W2595184800 hasAuthorship W2595184800A5033873028 @default.
• W2595184800 hasAuthorship W2595184800A5065609260 @default.
• W2595184800 hasAuthorship W2595184800A5076961983 @default.
• W2595184800 hasAuthorship W2595184800A5079494067 @default.
• W2595184800 hasAuthorship W2595184800A5079603579 @default.
• W2595184800 hasAuthorship W2595184800A5083377034 @default.
• W2595184800 hasBestOaLocation W25951848001 @default.
• W2595184800 hasConcept C126322002 @default.
• W2595184800 hasConcept C164705383 @default.
• W2595184800 hasConcept C188816634 @default.
• W2595184800 hasConcept C2775914520 @default.
• W2595184800 hasConcept C2776301958 @default.
• W2595184800 hasConcept C2777289489 @default.
• W2595184800 hasConcept C2778661090 @default.
• W2595184800 hasConcept C2778810321 @default.
• W2595184800 hasConcept C2779161974 @default.
• W2595184800 hasConcept C2780638905 @default.
• W2595184800 hasConcept C2909457131 @default.
• W2595184800 hasConcept C42219234 @default.
• W2595184800 hasConcept C71924100 @default.
• W2595184800 hasConceptScore W2595184800C126322002 @default.
• W2595184800 hasConceptScore W2595184800C164705383 @default.
• W2595184800 hasConceptScore W2595184800C188816634 @default.
• W2595184800 hasConceptScore W2595184800C2775914520 @default.
• W2595184800 hasConceptScore W2595184800C2776301958 @default.
• W2595184800 hasConceptScore W2595184800C2777289489 @default.
• W2595184800 hasConceptScore W2595184800C2778661090 @default.
• W2595184800 hasConceptScore W2595184800C2778810321 @default.
• W2595184800 hasConceptScore W2595184800C2779161974 @default.
• W2595184800 hasConceptScore W2595184800C2780638905 @default.
• W2595184800 hasConceptScore W2595184800C2909457131 @default.
• W2595184800 hasConceptScore W2595184800C42219234 @default.
• W2595184800 hasConceptScore W2595184800C71924100 @default.
• W2595184800 hasIssue "3" @default.
• W2595184800 hasLocation W25951848001 @default.
• W2595184800 hasLocation W25951848002 @default.
• W2595184800 hasLocation W25951848003 @default.

• next